Drug intelligence / Profile preview

SHR-A1811 + camrelizumab + famitinib

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

SHR-A1811 + camrelizumab + famitinib is a combination therapy being evaluated in the FUTURE-SUPER platform trial (NCT05656131) led by Fudan University for the treatment of refractory triple-negative breast cancer (TNBC). The combination consists of three distinct agents: SHR-A1811, a next-generation antibody-drug conjugate (ADC) targeting HER2; camrelizumab, a humanized monoclonal antibody targeting the PD-1 receptor; and famitinib, an oral multi-targeted tyrosine kinase inhibitor (TKI). SHR-A1811 delivers a cytotoxic topoisomerase I inhibitor payload directly to HER2-expressing tumor cells. Camrelizumab acts as a checkpoint inhibitor to restore T-cell mediated anti-tumor immunity. Famitinib inhibits angiogenesis and tumor cell proliferation by targeting VEGFR2, VEGFR3, PDGFR, and c-kit. This triplet regimen aims to overcome therapeutic resistance in TNBC by simultaneously targeting tumor cell survival, immune evasion, and the tumor microenvironment.

Other names: SHR-A1811 + camrelizumab + famitinib-Fudan University

Targets

PDCD1 (Programmed cell death protein 1 receptor)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFR (PDGFR family)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TOP1 (DNA Topoisomerase I)VEGFR3 (Vascular endothelial growth factor receptor 3)

Beyond the preview

Go deeper on SHR-A1811 + camrelizumab + famitinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-A1811 + camrelizumab + famitinib.

Explore the full profile